Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**CADI-T2011** is a proprietary, preclinical microbiota-based therapeutic protocol developed by Bio-Modeling Systems for autism spectrum disorder. The program is intended to modulate autism-associated gut dysbiosis and associated neuro-immune interactions, with the goal of attenuating core autism symptoms and potentially improving comorbid gastrointestinal dysfunction, sleep disorders, anxiety, and depression. The specific microbial composition, active constituents, formulation, dose, and route of administration have not been publicly disclosed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CADI-T2011.